Abstract
This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the associated risk of ventricular arrhythmia and fibrillation. The molecular characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation. The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to determine structure-activity relations (SAR) within chemical series. More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chemical series is a viable strategy to reduce or eliminate hERG activity. Despite a critical need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.
Keywords: hERG, Ikr, action potential, repolarization reserve, transmural dispersion of repolarization (TDR), QT prolongation, torsades de Pointes (TdP)
Current Topics in Medicinal Chemistry
Title: The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview
Volume: 8 Issue: 13
Author(s): Armando A. Lagrutta, Elena S. Trepakova and Joseph J. Salata
Affiliation:
Keywords: hERG, Ikr, action potential, repolarization reserve, transmural dispersion of repolarization (TDR), QT prolongation, torsades de Pointes (TdP)
Abstract: This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the associated risk of ventricular arrhythmia and fibrillation. The molecular characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation. The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to determine structure-activity relations (SAR) within chemical series. More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chemical series is a viable strategy to reduce or eliminate hERG activity. Despite a critical need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.
Export Options
About this article
Cite this article as:
Lagrutta A. Armando, Trepakova S. Elena and Salata J. Joseph, The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview, Current Topics in Medicinal Chemistry 2008; 8 (13) . https://dx.doi.org/10.2174/156802608785700016
DOI https://dx.doi.org/10.2174/156802608785700016 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging Frequency of Cardiac Arrhythmias in Children with Cardiological Consulting and Containing Electrocardiogram
Cardiovascular & Hematological Disorders-Drug Targets Effects of an Acute Treatment with L-Thyroxine on Memory, Habituation, Danger Avoidance, and on Na+, K+-ATPase activity in Rat Brain
Current Neurovascular Research Primary Heart Involvement in Systemic Sclerosis
Current Rheumatology Reviews Cardiac Resynchronization Therapy in Children
Current Cardiology Reviews Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Current Pharmaceutical Design Designing Recombinant Collagens for Biomedical Applications
Current Tissue Engineering (Discontinued) A Comparative Effectiveness Systematic Review and Meta-analysis of Drugs for the Prophylaxis of Junctional Ectopic Tachycardia
Current Cardiology Reviews Animal Models of Pulmonary Emphysema
Current Drug Targets - Inflammation & Allergy Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Closure of Patent Foramen Ovale: When and How?
Current Vascular Pharmacology The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry